A NLR greater than 3 and a PLR greater than 250 were associated with worse OS and DFS in Hispanic patients with breast cancer.

LNR was independently associated with OS and DFS in patients with colon adenocarcinoma regardless of its clinical stage.

No abstract

No abstract

INTRODUCTION: Tumor size has long been recognized as the strongest predictor of the outcome of patients with breast cancer. While screening programs are increasing the proportion of non-palpable breast cancer cases, it is important to know its relevance in the outcome. Our purpose was to evaluate various prognostic factors, including tumor palpability, in a multivariate fashion. METHODS: A Kaplan-Meier survival analysis was carried out for a retrospective cohort of 758 women with early stages of invasive breast carcinomas who were treated at the Breast Unit of the CECLINES (Caracas-Venezuela), Clinica el Viñedo y Centro Medico Dr. Rafael Guerra Mendez and University of Carabobo (Valencia-Venezuela), between 1987-2010. Endpoints were 10 years disease free survival (10 yrs-DFS) and 10 years overall survival (10 yrs-OS). Using a multivariate analysis, Hazard ratios (HR) were calculated in order to identify independent prognostic factors for 10 yrs-DFS and 10 yrs-OS. RESULTS: The median age for the entire cohort was 55yo; 293 (38.7%) tumors were not palpable and 465 (61.3%) were palpable; 42.2% (318 cases) were in pathological stage (PS) I and 57.8% (436 cases) in PS II. Tumor size was <1cm in 26% of cases; was between 1 - 3cm in 24.9% and >3cm in 49.1%; 23.2% had nodal involvement. In regard to immunohistochemistry markers, 633 were evaluable for estrogen receptor (ER); 599 for progesterone receptor (PR) and 578 for HER2. In regard to the status for these markers, 76.9% were ER+; 68.4% PR+ and 28.4% HER2+. Patients more likely to have non palpable tumors were ≥45yo (p = 0.001); smaller tumors (p<0.001); negative lymph nodes (p = 0.008); HER2 negative tumors (p = 0.001) and pathological stage I (p<0.001). The median of follow up was 42.6 months. The 10yrs-DFS was 78.7% and the 10yrs-OS was 91%. There were significant differences in 10yrs-DFS according to tumor palpability (non-palpable 81.1% vs palpable 73.3%, p = 0.002); tumor size (<1cm 81.7% vs 1-3cm 78.3% vs >3cm 77.3%, p = 0.017); nodal involvement (negative 81.9% vs positive 67.2%, p = 0.054); PS (I-IIA: 89.4% vs IIB, 74.9%, p<0.001); treatment with radiotherapy (yes 79% vs no 65.9%) and hormonotherapy (yes 78.9% vs no 70.1%). For 10yrs-OS, there were significant differences in palpability (palpable 78.2% vs non palpable 86.9%, p<0.001); tumor size (<1cm 96% vs 1-3cm 87.6% vs >3cm 75.3%, p = 0.027); HER2 (positive 95.9% vs negative 87.4%, p = 0.052); PS (I-IIA: 95.4% vs IIB, 86.5%, p<0.016) and radiotherapy (yes 92.7% vs no 79.1%, p = 0.001). In the multivariate analysis for 10 yrs-DFS, significant variables were: palpability (HR = 0.43 for non-palpable tumors, CI 95%: 0.242-0.781; p = 0.005) and radiotherapy (HR = 2.5 for patients that did not undergo radiotherapy, CI 95% 1.44 - 4.23). For 10 yrs-OS significant variables were HER2 (HR = 3.6 for HER2+, CI 95%: 1.18 - 10.86, p = 0.024). There was a statistical trend with palpability (HR = 0.23 for non-palpable tumors, CI 95%: 0.05-1.06; p = 0.06). CONCLUSIONS Women with early stage breast cancers with non-palpable tumors were less likely to present disease recurrence, independently of other factors. In the era of genomic profiling, a variable easily assessed in routine could be a surrogate factor for disease free survival. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-41.